CCL17 and lung adenocarcinoma: The specific lysis of CCR4-positive cells in the lower chamber of treatment group A (100 ng/ml CCL17) on HLA-A2-positive lung adenocarcinoma H1993 cells was significantly stronger than that of treatment group B (without CCL17), and the difference was significant (p < 0.05).